Olaparib: observed
40 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- PROLONG (PRostateOLaparibONcombinationGcc) StudyNot yet recruitingNCT07674121Report a problem
- Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer PatientsRecruitingNCT07151911Report a problem
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingNCT07066917Report a problem
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruitingNCT06995833Report a problem
- NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)RecruitingNCT06890273Report a problem
- Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world ScenarioRecruitingNCT06836219Report a problem
- Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate CancerRecruitingNCT06783127Report a problem
- Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian CancerRecruitingNCT06572735Report a problem
- Intensive Adjuvant Therapy for TNBC with BRCA Gene MutationEnrolling by invitationNCT06405295Report a problem
- Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.Enrolling by invitationNCT04699006Report a problem
- Preoperative Olaparib Endometrial Carcinoma Study (POLEN)CompletedNCT02506816Results postedReport a problem
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNCT07477756Report a problem
- Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)WithdrawnNCT07475923Report a problem
- Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+AbirateroneWithdrawnNCT06457854Report a problem
- Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Active, not recruitingNCT06380738Report a problem
- Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World SettingCompletedNCT06324734Report a problem
- PRostate Olaparib Real World Evidence StudyActive, not recruitingNCT06031805Report a problem
- A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerCompletedNCT05775549Report a problem
- LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)CompletedNCT05677308Report a problem
- First-line Olaparib Combined With Bevacizumab Maintenance TherapyStatus unknownNCT05440578Report a problem
- Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical SettingStatus unknownNCT05153603Report a problem
- The Effect of Glucose Level and Diabetes Mellitus on Ctrough of OlaparibStatus unknownNCT05081765Report a problem
- Homologous Recombination Deficiency in Chinese Ovarian Cancer PatientsStatus unknownNCT05044091Report a problem
- LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)CompletedNCT04889404Report a problem
- Pancytopenia Related to PARP Inhibitors (PancytoRIB)CompletedNCT04774627Report a problem
- Arterial Hypertension Related to PARP Inhibitors (ArteRIB)CompletedNCT04774406Report a problem
- The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian CancerStatus unknownNCT04582552Report a problem
- Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsCompletedNCT04560452Report a problem
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926Report a problem
- Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKCompletedNCT04532645Report a problem
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)CompletedNCT04326023Report a problem
- Real-life Data of Olaparib in Relapsed Ovarian Cancers PatientsCompletedNCT04152941Report a problem
- Breast Cancer Treatment Based on Organ-like CultureStatus unknownNCT03925233Report a problem
- Lynparza Breast Cancer Clinical Experience InvestigationCompletedNCT03590938Report a problem
- Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)CompletedNCT03505307Report a problem
- Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Approved for marketingNCT03079687Report a problem
- Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in JapanNo longer availableNCT03063710Report a problem
- C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationCompletedNCT02503436Report a problem
- A Study of Long-Term Responders on OlaparibCompletedNCT02489058Report a problem
- OSCA - Olaparib Standard of CAre StudyCompletedNCT02262273Report a problem